company background image
B8FK logo

Biofrontera DB:B8FK Stock Report

Last Price

€2.21

Market Cap

€13.8m

7D

5.3%

1Y

-77.4%

Updated

10 Jan, 2025

Data

Company Financials

Biofrontera AG

DB:B8FK Stock Report

Market Cap: €13.8m

B8FK Stock Overview

A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. More details

B8FK fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings have grown 9.6% per year over the past 5 years

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (€14M)

Volatile share price over the past 3 months compared to the German market


My Notes

Capture your thoughts, links and company narrative

Biofrontera AG Competitors

SynBiotic

DUSE:SBX

€21.9m

Cantourage Group

XTRA:HIGH

€60.1m

Apontis Pharma

XTRA:APPH

€85.0m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of share price highs, lows and changes for Biofrontera
Historical stock prices
Current Share Price€2.21
52 Week High€10.63
52 Week Low€2.03
Beta0.44
1 Month Change0.23%
3 Month Change-26.50%
1 Year Change-77.37%
3 Year Change-92.91%
5 Year Change-97.94%
Change since IPO-99.30%

Recent News & Updates

Recent updates

Shareholder Returns

B8FKDE PharmaceuticalsDE Market
7D5.3%2.5%1.3%
1Y-77.4%-15.2%9.0%

Return vs Industry: B8FK underperformed the German Pharmaceuticals industry which returned -14.1% over the past year.

Return vs Market: B8FK underperformed the German Market which returned 10.1% over the past year.

Price Volatility

Is B8FK's price volatile compared to industry and market?
B8FK volatility
B8FK Average Weekly Movement11.4%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: B8FK's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: B8FK's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199778n/awww.biofrontera.com

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin.

Biofrontera AG Fundamentals Summary

How do Biofrontera's earnings and revenue compare to its market cap?
B8FK fundamental statistics
Market cap€13.79m
Earnings (TTM)-€357.00k
Revenue (TTM)€18.17m

0.8x

P/S Ratio

-38.6x

P/E Ratio

Is B8FK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B8FK income statement (TTM)
Revenue€18.17m
Cost of Revenue€4.85m
Gross Profit€13.32m
Other Expenses€13.68m
Earnings-€357.00k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Apr 30, 2025

Earnings per share (EPS)-0.059
Gross Margin73.31%
Net Profit Margin-1.96%
Debt/Equity Ratio0%

How did B8FK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 06:53
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biofrontera AG is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Navid MalikCavendish Historical (Cenkos Securities)
Robert WassermanDawson James Securities